Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab-Reference-Cited by-同舟云学术

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Published:2021-05-03 Issue:10 Volume:11 Page:2474-2487
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Filho Otto Metzger,Viale Giuseppe,Stein Shayna,Trippa Lorenzo,Yardley Denise A.,Mayer Ingrid A.,Abramson Vandana G.^ORCID,Arteaga Carlos L.,Spring Laura M.,Waks Adrienne G.^ORCID,Wrabel Eileen,DeMeo Michelle K.,Bardia Aditya,Dell'Orto Patrizia^ORCID,Russo Leila,King Tari A.,Polyak Kornelia^ORCID,Michor Franziska,Winer Eric P.^ORCID,Krop Ian E.^ORCID

Funder

NCI

National Cancer Institute

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

2. Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer;Journal of Nuclear Medicine;2024-09-05

3. Quantitative Measurement of HER2 Expression in Non–Small Cell Lung Cancer With a High-Sensitivity Assay;Modern Pathology;2024-09

4. HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment;Journal of Cancer Research and Clinical Oncology;2024-08-28

5. Imaging and Monitoring HER2 Expression in Tumors during HER2 Antibody–Drug Conjugate Therapy Utilizing a Radiolabeled Site-Specific Single-Domain Antibody Probe: ⁶⁸Ga-NODAGA-SNA004-GSC;Journal of Medicinal Chemistry;2024-07-30